Clinical Trial Update: Safety, Tolerability, Pharmacokinetics, and Anti-Retroviral Activity of MK-8558 Monotherapy in Anti-Retroviral-Naïve HIV-1 Infected Participants (MK-8558-002) [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating safety, tolerability, PK, and anti-retroviral activity of MK-8558 monotherapy in ART-naïve HIV-1-infected participants; results posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• MK-8558 (MK-8558)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: HIV-1 Infection | Phase 1 | Status: COMPLETED | Results posted: 2021-05-28